↓ Skip to main content

Dove Medical Press

Article Metrics

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

Overview of attention for article published in Drug Design, Development and Therapy, April 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
31 Mendeley
Title
<p>Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura</p>
Published in
Drug Design, Development and Therapy, April 2019
DOI 10.2147/dddt.s134470
Authors

Tugrul Elverdi, Ahmet Emre Eskazan

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 19%
Other 3 10%
Student > Postgraduate 2 6%
Student > Ph. D. Student 2 6%
Student > Bachelor 1 3%
Other 5 16%
Unknown 12 39%
Readers by discipline Count As %
Medicine and Dentistry 9 29%
Biochemistry, Genetics and Molecular Biology 3 10%
Agricultural and Biological Sciences 2 6%
Veterinary Science and Veterinary Medicine 1 3%
Unspecified 1 3%
Other 1 3%
Unknown 14 45%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2019.
All research outputs
#9,972,525
of 15,657,453 outputs
Outputs from Drug Design, Development and Therapy
#644
of 1,588 outputs
Outputs of similar age
#162,077
of 271,078 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 1 outputs
Altmetric has tracked 15,657,453 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,588 research outputs from this source. They receive a mean Attention Score of 4.6. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,078 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them